ALXO ALX Oncology Holdings Inc.: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik ALX Oncology Holdings Inc. (ALXO)

High dependence on a single CD47 blocking method creates significant risks for ALX Oncology Holdings (ALXO). This EV/Sales chart helps identify areas of market overvaluation for the asset, where 0.00 serves as the base parameter value. US-based research and a next-generation platform support the business's stability. A competitive advantage is provided by the drug evorpacept, which effectively destroys tumors while preserving erythrocytes.

Nilai perusahaan marang pendapatan: ALX Oncology Holdings Inc. (ALXO) kanggo 23.11.2025 - 21.11.2026

alxoncology.com - rincian analitis lan metrik utama (ALXO)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:ALX Oncology Holdings ALXO
Sampel barang ALX Oncology Holdings

This multiple compares the total enterprise value of ALX Oncology Holdings (ALXO) with its annual revenue, excluding the impact of leverage to determine the actual market value of the assets. By analyzing the EV/Sales valuation ratio, an investor determines the extent of priced-in expectations regarding the success of CD47 immunotherapy, where a high valuation reflects the potential for breakthrough clinical trials by ALX Oncology Holdings (ALXO) in the fight against cancer.

Analisis pesaing ALX Oncology Holdings

IBRX (immunitybio.com) - Rasio nilai perusahaan marang pendapatan|Immunocore Corp (IMCR) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Janux Pharma (JANX)|Nilai perusahaan marang pendapatan RCUS|ZYME - Rasio nilai perusahaan marang dodolan|Nilai perusahaan marang pendapatan TNGX (Tango Pharma)|Koefisien nilai perusahaan marang pendapatan IOVA|Multiplikator EV/Sales IMTX (Immatics)|Nilai bisnis marang pendapatan XNCR|compasstherapeutics.com - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Replimune Inc.|Lyell Immunopharma (LYEL) - Rasio nilai perusahaan marang pendapatan|Innate Pharma S.A. - Nilai bisnis marang pendapatan|PYXS (Pyxis) - Multiplikator EV/Sales|Multiplikator EV/Sales cgen.com|Rasio nilai perusahaan marang pendapatan IO Biotech (IOBT)|STRO: Nilai perusahaan marang volume dodolan|MiNK Therapeutics Inc. - Nilai perusahaan marang pendapatan|werewolftx.com (HOWL) - Multiplikator nilai perusahaan marang pendapatan|Immix Biopharma Inc. - Multiplikator EV/Sales|CUE - Multiplikator EV/Sales|PDSB: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Liminatus Pharma (LIMN)|Multiplikator EV/Sales LVTX|Koefisien nilai perusahaan marang pendapatan NXTC|Leap Therapeutics, Inc. - Nilai perusahaan marang pendapatan|INTS: Rasio nilai perusahaan marang pendapatan|Sensei Biotherapeutics Inc - Multiplikator EV/Sales|TOVX: Rasio nilai perusahaan marang pendapatan|gritstonebio.com (GRTS) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan KA|Rasio nilai perusahaan marang pendapatan NexImmune, Inc.|Rasio nilai perusahaan marang pendapatan TSBX (Turnstone Biologics)|Nilai perusahaan marang pendapatan VCNX (Vaccinex, Inc.)|Koefisien nilai perusahaan marang pendapatan HARP